| INTRODUCTION
Dumping syndrome is a debilitating complication of oesophageal and gastric surgery, and has been estimated to occur in 20%-50% of patients after oesophagectomy or gastrostomy. 1, 2 In recent years, the prevalence of dumping syndrome has been rising because of the increasing number of patients undergoing bariatric surgery in the form of Roux-en-Y gastric bypass. [2] [3] [4] [5] The symptoms of dumping syndrome are characteristically triggered by meal ingestion and can be categorised into early and late postprandial symptoms. 2 Early symptoms occur in the first hour after meal ingestion and are attributed to consequences of the rapid delivery of undigested nutrients into the jejunum causing a fluid shift from the intravascular component to the intestinal lumen and increased secretion of various intestinal hormones and vasoactive agents. 2 This results in gastrointestinal (abdominal pain, diarrhoea, borborygmi, bloating, nausea) and vasomotor (flushing, palpitations, perspiration, tachycardia, hypotension, syncope) symptoms. 2, 4, 6 Late symptoms typically occur within 1-3 h after the meal and are attributed to reactive hypoglycaemia. 2, 4, 6 The estimated prevalence rate of hypoglycaemia after gastric bypass surgery varies from 10% to 72%, depending upon the definition of hypoglycaemia, the hypoglycaemia-inducing stimulus and the population studied. 7, 8 Owing to such a symptom profile, dumping syndrome can severely impact patients' quality of life (QOL). 9 The first-line approach to the management of dumping syndrome is dietary modification which is effective mostly in patients with mild symptoms. 10 Currently, there is no approved medical treatment available for patients with dumping syndrome. 11 Use of acarbose 2 and diazoxide 12 in some patients have been reported to improve late dumping symptoms. Octreotide, a first-generation somatostatin analogue approved for use in acromegaly and gastroenteropancreatic neuroendocrine tumours, administered either as subcutaneous (SC) or as intramuscular (IM) long-acting injection, has been used off-label for the treatment of patients with dumping syndrome in whom firstline measures fail. 1, [13] [14] [15] Octreotide provides symptomatic relief in patients with early and late dumping syndrome by delaying gastrointestinal transit, inhibiting insulin secretion and preventing postprandial splanchnic vasodilatation. [16] [17] [18] [19] However, a long-term follow-up study of octreotide in patients with dumping syndrome showed that up to 60% of patients discontinued therapy, mostly due to adverse effects (26.5%) or loss of efficacy (20.6%). 6 Therefore, a substantial unmet need persists in the medical therapy of dumping syndrome.
Pasireotide, a second-generation somatostatin analogue with high affinity for somatostatin receptors 5 (SSTR5) and somatostatin receptors 2 (SSTR2), is approved for the treatment of patients with
Cushing disease 20 and acromegaly. 21 Compared with octreotide, pasireotide has a 39-fold higher affinity to SSTR5 and 0.4-fold lower affinity for SSTR2. 22, 23 SSTR2 and SSTR5 also play important roles in blood glucose regulation by inhibiting the secretion of glucagon (SSTR2) and insulin (SSTR2 and SSTR5). Stronger inhibition of insulin as compared to glucagon is expected due to the differential binding of pasireotide, and this may lead to elevation in blood glucose levels via dominant inhibition of insulin over glucagon secretion. [24] [25] [26] [27] A proof-of-concept study in patients with dumping syndrome (N = 9) showed that pasireotide SC 300 lg three times daily (t. The study was conducted in accordance with the Declaration of Helsinki, and an independent ethics committee or institutional review board for each study site approved the study protocol. All patients provided written informed consent to participate in the study. The ClinicalTrials.gov identifier is NCT01637272.
All authors had access to study data and reviewed and approved the final manuscript. 
| Study design

| Statistical analyses
This study is exploratory in nature, and therefore, no formal hypotheses were set. This study was designed based on the 
| Patient demographics
Patient demographics, characteristics and disease history by treatment period are presented in 
| Improvement in haematocrit
In the SC phase, at study entry, 27.9% (12 of 43) of the patients had a ≥3% of increase in haematocrit during OGTT, which reduced to 16 .3% (7 of 43) of the patients at month 3. Among the patients who switched to IM phase (N = 33), the proportion of patients with this increase in haematocrit during OGTT at months 6 and 12 were 27.3% (9 of 33) and 24.2% (8 of 33), respectively.
| Patient-reported outcomes
The mean patient global assessment scores improved from baseline to the end of the 3-month SC dose-escalation phase (46.2% of increase from SC baseline). With the switch to the IM formulation, the improvement observed in the SC phase was maintained at month 6 (1.5% of increase from IM baseline). The scores further improved at month 12 (12.1% of increase from IM baseline). At the end of SC dose-escalation phase (month 3), the mean percentage increase from study baseline in PCS was 3.3% and MCS was 8.3%.
Consistent with the SC dose-escalation phase, the mean percentage increase from the baseline of pasireotide IM to month 6 for physical and MCS of SF-36 were 0.9% and 3.9%, respectively. At month 12, the physical and MCS of SF-36 was maintained (0.2% of decrease and 3% of increase from IM baseline respectively). Treatment with pasireotide improved the mean overall DSS score and DSQ score.
Additionally, improvement was observed in both early and late dumping symptoms as assessed by DSS and DSQ scores (Table 3) .
| Insulin, glucagon, GLP-1 and GIP levels
Treatment with pasireotide SC was associated with a decrease from baseline in the mean insulin, glucagon, GLP-1 and GIP levels at all the time points during the OGTT. Consistent with the SC dose-escalation phase, the insulin, glucagon, GLP-1 and GIP levels remained lower than baseline at months 6 and 12 ( Figure 3B -E).
| Safety and tolerability
Overall, 38 patients (88.4%) experienced at least 1 AE during the 12 months of the study (Table 4) (≥2 patients) were hypoglycaemia (n = 3, 7.0%), abdominal adhesions and small intestinal obstruction (n = 2, 4.7% each). Twenty patients (46.5%) discontinued during the 12-month study ( Figure 2 ); of these, 10 patients discontinued when receiving pasireotide IM. Six patients discontinued due to AEs, of whom, 5 discontinued during the SC phase (1 patient due to asthenia and weight gain; 1 patient due to abdominal pain, nausea and vomiting; 1 patient due to ECG QT prolonged; 1 patient due to prothrombin level abnormal; 1 patient due to vomiting, oedema, angina pectoris and micturition frequency decreased) and 1 patient discontinued during IM phase due to secondary adrenocortical insufficiency. All except 1 AE leading to discontinuation (weight gain) were suspected to be related to study treatment.
Adverse events of hyperglycaemia were reported in 5 patients No patient had QTcF >500 ms during the study. Two patients (4.7%) had an increase from study baseline in QTcF of >60 ms during the entire study. There were no deaths during the study. (Table S1 ). Other exploratory pharmacokinetic analyses (eg PK/efficacy) and estimated PK parameters are presented in Supporting information. and noncompliance. 1, 6 Although octreotide IM provides a more convenient monthly administration schedule and has beneficial effects, up to 60% of patients with dumping syndrome were found to either discontinue treatment or have an inadequate response in the long term. 6 Pasireotide, a next-generation somatostatin analogue, is a potent inhibitor of growth hormone and adrenocorticotropic hormone, and is therefore an effective medical therapy for patients with acromegaly and Cushing disease respectively. 30, 31 Although the general safety profile of pasireotide in patients with acromegaly and Cushing disease was found to be consistent with that of first-generation somatostatin analogues, treatment-related hyperglycaemia was more frequently reported in patients receiving pasireotide treatment. [30] [31] [32] Pasireotide has a higher binding affinity for SSTR5 and similar affinity for SSTR2 when compared to (D) Pasireotide SC and IM were generally well tolerated in this study.
The most common AEs reported in the trial were symptoms commonly reported in patients with dumping syndrome. AEs of hyperglycaemia (11.6%) were less frequent in this patient population than what has been reported in other indications (50%-60%); however, the current study was relatively restrictive in the inclusion and exclusion criteria related to glycaemic parameters. 30, 31, 38, 39 No new safety signals were identified in the dumping syndrome population.
Pharmacokinetic/efficacy analyses supported the clinical findings and suggested that increasing pasireotide dose is likely to produce greater suppression of insulin, glucagon, GLP-1 and GIP levels.
An additional subgroup analysis based on the response status at month 3 was performed. Mean change in glucose, insulin and glucagon over time was evaluated, and no major differences were observed among the 2 subgroups. Furthermore, the baseline characteristics such as age, sex, time since surgery, type of surgery, body mass index, baseline FPG and HbA 1c were studied and found to be similar across the 2 subgroups.
No clear predictive factors for the response could be identified.
The findings from this study were consistent with the findings of the pilot study. 4 The pilot study had evaluated 300 lg doses of pasireotide SC for a short period. The dose-escalation phase allowed patients to reach the dose that effectively prevents the hypogly- it eliminates an additional glycaemia-lowering effect of physical activity. Lastly, the number of patients studied is relatively small.
However, it should be recognised that this study is among the largest studies conducted in patients with dumping syndrome to date. A sample size of 43 patients was determined for this study based on statistical considerations in keeping with the expected range for the response rate (50%-70%) and dropout rate (0%-30%).
In conclusion, pasireotide reduced the incidence of hypoglycaemia and improved the symptoms of both early and late dumping T A B L E 4 Most frequent AEs (≥10% in any phase), regardless of study drug relationship, by preferred term (safety analysis set) 
